Scarica l'app Stockscreener
26.13
1.51%
-0.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Alkermes Plc Borsa (ALKS) Ultime notizie
Is Alkermes plc a growth stock or a value stockUnlock steady growth with low-risk stocks - jammulinksnews.com
What drives Alkermes plc stock priceSuperior capital gains - Autocar Professional
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN
Abivax’s miRNA therapy emerges as a new mechanism for ulcerative colitis - BioCentury
Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN
What analysts say about Alkermes plc stockHigh-yield portfolio picks - Autocar Professional
Alkermes plc Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com
Is Alkermes plc a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - The Globe and Mail
Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Alkermes stock holds steady as H.C. Wainwright maintains Neutral rating By Investing.com - Investing.com UK
Alkermes Announces Positive Phase 2 Study Results - TipRanks
Oversold Conditions For Alkermes (ALKS) - Nasdaq
Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results - insights.citeline.com
Jefferies Raises Target for Alkermes (ALKS) Following Promising Drug Data | ALKS Stock News - GuruFocus
Why Alkermes Tumbled On Its Positive Narcolepsy Study - inkl
Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study - inkl
Why Is Alkermes Stock Falling On Monday?Alkermes (NASDAQ:ALKS) - Benzinga
Alkermes stock falls after BofA maintains Neutral rating on narcolepsy drug - Investing.com UK
Alkermes narcolepsy drug headed for late-stage testing - BioPharma Dive
Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat
Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data - Investing.com UK
Alkermes Vibrance-1 Phase 2 Study Of Alixorexton In Narcolepsy Type 1 Meets Primary Goal - Nasdaq
Alkermes narcolepsy drug shows positive results in phase 2 trial By Investing.com - Investing.com Nigeria
Alkermes narcolepsy drug shows positive results in phase 2 trial - Investing.com
Alkermes announces positive topline results from Vibrance-1 Phase 2 study - MarketScreener
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire
Alkermes Orexin Receptor Agonist Shows Broad Benefits in Phase 2 Narcolepsy Study - Sleep Review
Is Alkermes Plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals? - 富途牛牛
10 Most Undervalued Pharma Stocks to Buy Now - Insider Monkey
BlackRock increases stake in Alkermes to 17.05% By Investing.com - Investing.com India
BlackRock increases stake in Alkermes to 17.05% - Investing.com
2.82%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):